Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest BAKER BROS. ADVISORS LP Stock Portfolio

$7.97Billion– No. of Holdings #87

BAKER BROS. ADVISORS LP Performance:
2024 Q1: -7.58%YTD: -7.58%2023: 25.53%

Performance for 2024 Q1 is -7.58%, and YTD is -7.58%, and 2023 is 25.53%.

About BAKER BROS. ADVISORS LP and 13F Hedge Fund Stock Holdings

BAKER BROS. ADVISORS LP is a hedge fund based in NEW YORK, NY. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $23.2 Billions. In it's latest 13F Holdings report, BAKER BROS. ADVISORS LP reported an equity portfolio of $8 Billions as of 31 Mar, 2024.

The top stock holdings of BAKER BROS. ADVISORS LP are INCY, BGNE, ACAD. The fund has invested 25.9% of it's portfolio in INCYTE CORPORATION and 20.7% of portfolio in BEIGENE, LTD.

The fund managers got completely rid off MIRATI THERAPEUTICS, INC. (MRTX), GRACELL BIOTECHNOLOGIES INC. (GRCL) and DAY ONE BIOPHARMACEUTICALS, INC. (DAWN) stocks. They significantly reduced their stock positions in PERSPECTIVE THERAPEUTICS, INC., ACHILLES THERAPEUTICS PLC (ACHL) and IMMUNOCORE HOLDINGS PLC (IMCR). BAKER BROS. ADVISORS LP opened new stock positions in FATE THERAPEUTICS, INC. (FATE), NEUMORA THERAPEUTICS, INC. and DYNE THERAPEUTICS, INC. (DYN). The fund showed a lot of confidence in some stocks as they added substantially to CELCUITY INC. (CELC), BICYCLE THERAPEUTICS PLC (BCYC) and XENCOR, INC. (XNCR).
BAKER BROS. ADVISORS LP Equity Portfolio Value
Last Reported on: 15 May, 2024

BAKER BROS. ADVISORS LP Annual Return Estimates Vs S&P 500

Our best estimate is that BAKER BROS. ADVISORS LP made a return of -7.58% in the last quarter. In trailing 12 months, it's portfolio return was -1.09%.

New Buys

Ticker$ Bought
fate therapeutics, inc.13,345,400
neumora therapeutics, inc.8,715,450
dyne therapeutics, inc.8,091,150
praxis precision medicines, inc.8,026,140
sage therapeutics, inc.7,631,250
alpine immune sciences, inc.3,233,750
4d molecular therapeutics, inc.3,186,000
newamsterdam pharma company n.v.2,289,960

New stocks bought by BAKER BROS. ADVISORS LP

Reductions

Ticker% Reduced
perspective therapeutics, inc.-98.04
achilles therapeutics plc-42.52
immunocore holdings plc-39.89
opthea limited-15.87
sagimet biosciences inc.-5.12
roivant sciences ltd.-2.36
adaptimmune therapeutics plc-1.66

BAKER BROS. ADVISORS LP reduced stake in above stock

Sold off

Ticker$ Sold
invitae corporation-131,152,000
invitae corporation-6,272,700
mirati therapeutics, inc.-242,135,000
atreca, inc.-287,430
gracell biotechnologies inc.-20,883,200
ars pharmaceuticals, inc.-10,995,400
invitae corporation-1,106,020
day one biopharmaceuticals, inc.-14,600,000

BAKER BROS. ADVISORS LP got rid off the above stocks

Sector Distribution

BAKER BROS. ADVISORS LP has about 96.2% of it's holdings in Healthcare sector.

Sector%
Healthcare96.2
Others3.8

Market Cap. Distribution

BAKER BROS. ADVISORS LP has about 46.6% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
MID-CAP28.9
LARGE-CAP25.9
MEGA-CAP20.7
SMALL-CAP17.2
UNALLOCATED3.8
MICRO-CAP3.4

Stocks belong to which Index?

About 68.3% of the stocks held by BAKER BROS. ADVISORS LP either belong to S&P 500 or RUSSELL 2000 index.

Index%
RUSSELL 200042.4
Others31.7
S&P 50025.9
Top 5 Winners (%)%
STOK
stoke therapeutics, inc.
156.5 %
VTVT
vtv therapeutics, inc.
126.3 %
TARA
protara therapeutics, inc.
113.9 %
SANA
sana biotechnology, inc.
110.4 %
ADAP
adaptimmune therapeutics plc
98.6 %
Top 5 Winners ($)$
KYMR
kymera therapeutics, inc.
88.4 M
MDGL
madrigal pharmaceuticals, inc.
70.2 M
KOD
kodiak sciences inc.
38.4 M
STOK
stoke therapeutics, inc.
27.7 M
EWTX
edgewise therapeutics, inc.
26.3 M
Top 5 Losers (%)%
PMVP
pmv pharmaceuticals, inc.
-45.2 %
ACAD
acadia pharmaceuticals inc.
-41.0 %
LPTX
leap therapeutics, inc.
-35.8 %
CABA
cabaletta bio, inc.
-24.9 %
RLAY
relay therapeutics, inc.
-24.6 %
Top 5 Losers ($)$
ACAD
acadia pharmaceuticals inc.
-549.5 M
BGNE
beigene, ltd.
-253.3 M
INCY
incyte corporation
-210.6 M
ABCL
abcellera biologics inc.
-29.4 M
RYTM
rhythm pharmaceuticals, inc.
-16.9 M

BAKER BROS. ADVISORS LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS LP has 87 stocks in it's portfolio. About 77.1% of the portfolio is in top 10 stocks. ACAD proved to be the most loss making stock for the portfolio. KYMR was the most profitable stock for BAKER BROS. ADVISORS LP last quarter.

Last Reported on: 15 May, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions